Short-Term Medical Cannabis Treatment Regimens Produced Beneficial Effects among Palliative Cancer Patients

• Egile Nagusiak: Joshua Aviram (Egilea), Gil M. Lewitus (Egilea), Yelena Vysotski (Egilea), Anton Uribayev (Egilea), Shiri Procaccia (Egilea), Idan Cohen (Egilea), Anca Leibovici (Egilea), Mahmud Abo-Amna (Egilea), Luiza Akria (Egilea), Dmitry Goncharov (Egilea), Neomi Mativ (Egilea), Avia Kauffman (Egilea), Ayelet Shai (Egilea), Or Hazan (Egilea), Gil Bar-Sela (Egilea), David Meiri (Egilea)
• Formatua: Liburua
• Argitaratua: MDPI AG, 2020-11-01T00:00:00Z.
• Gaiak: article
• Sarrera elektronikoa: Connect to this object online.

In the last decade the use of medical cannabis (MC) for palliative cancer treatment has risen. However, the choice between products is arbitrary and most patients are using Tetrahydrocannabinol (THC)-dominant cannabis products. In this study, we aimed to assess the short-term outcomes of MC treatmen...